<DOC>
	<DOCNO>NCT01773798</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacodynamic ( effect investigate drug body ) pharmacokinetic ( exposure trial drug body ) property insulin degludec/insulin aspart 15 subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Pharmacodynamic Pharmacokinetic Properties Insulin Degludec/Insulin Aspart 15 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Body mass index 18.028.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking , use nicotine substitute product transdermal nicotine patch inpatient period Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure include sterilisation , hormonal intrauterine device , oral contraceptive , condom spermizide , sexual abstinence vasectomise partner )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>